Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Better COVID Outcomes Confirmed in TNF Inhibitor UsersA study of three international registries confirms that patients with immune-mediated inflammatory diseases who are taking
a TNF inhibitor should continue the treatment unless otherwise indicated.
Ruxolitinib Cream Meets Endpoints in Phase 3 Vitiligo TrialA topical formulation of the JAK inhibitor ruxolitinib produced statistically significant improvement in all primary and secondary
outcomes relative to vehicle alone at 24 weeks.